Panitumumab Induced Forearm Panniculitis in Two Women With Metastatic Colon Cancer / Ciliberto Domenico, Ierardi Antonella, Caroleo Benedetto, Scalise Luigi, Cimellaro Antonio, Colangelo Lidia, Spaziano Giuseppe, Luca Gallelli
Background: Panitumumab is an EGFR inhibitor used for the treatment of metastatic colorectal cancer (mCRC), even if its use is related to skin toxicity. Case Presentation: We report the development of forearm panniculitis in two women during the treatment with Panitumumab (6 mg/Kg intravenous every 2 weeks) + FOLFOX-6 (leucovorin, 5- fluorouracil, and oxaliplatin at higher dosage) for the treatment of mCRC. Results: In both patients, clinical, laboratory and radiological evaluation documented the presence of a local panniculitis, probably related to panitumumab (Naranjo score: 6). Panatimumab discontinuation and antimicrobial + corticosteroid treatment induced a remission of skin manifestations. Conclusion: We reported for the first time the development of panniculitis during Panitumumab treatment, and we documented that the treatment with beta-lactams to either fluoroquinolones or oxazolidinone in the presence of corticosteroid improves clinical symptoms in young patients with mCRC, without the development of adverse drug reactions or drug-drug interactions.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Current drug safety - 14(2019), 3, Seite 233- |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Domenico, CilibertoCiliberto [VerfasserIn] |
|---|
| Links: |
FID Access [lizenzpflichtig] |
|---|
| Umfang: |
1 Online-Ressource (5 p) |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
KFL001019066 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | KFL001019066 | ||
| 003 | DE-627 | ||
| 005 | 20231129085215.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210608s2019 xx |||||o 00| ||eng c | ||
| 035 | |a (DE-627)KFL001019066 | ||
| 035 | |a (KFL)prod_DARH_.7C4EB1EB91C3C11D8AB82E86AEEB7497AE6C9563 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 100 | 1 | |a Domenico, CilibertoCiliberto |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Panitumumab Induced Forearm Panniculitis in Two Women With Metastatic Colon Cancer |c Ciliberto Domenico, Ierardi Antonella, Caroleo Benedetto, Scalise Luigi, Cimellaro Antonio, Colangelo Lidia, Spaziano Giuseppe, Luca Gallelli |
| 264 | 1 | |c 2019 | |
| 300 | |a 1 Online-Ressource (5 p) | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Background: Panitumumab is an EGFR inhibitor used for the treatment of metastatic colorectal cancer (mCRC), even if its use is related to skin toxicity. Case Presentation: We report the development of forearm panniculitis in two women during the treatment with Panitumumab (6 mg/Kg intravenous every 2 weeks) + FOLFOX-6 (leucovorin, 5- fluorouracil, and oxaliplatin at higher dosage) for the treatment of mCRC. Results: In both patients, clinical, laboratory and radiological evaluation documented the presence of a local panniculitis, probably related to panitumumab (Naranjo score: 6). Panatimumab discontinuation and antimicrobial + corticosteroid treatment induced a remission of skin manifestations. Conclusion: We reported for the first time the development of panniculitis during Panitumumab treatment, and we documented that the treatment with beta-lactams to either fluoroquinolones or oxazolidinone in the presence of corticosteroid improves clinical symptoms in young patients with mCRC, without the development of adverse drug reactions or drug-drug interactions | ||
| 700 | 1 | |a Antonella, Ierardi |e verfasserin |4 aut | |
| 700 | 1 | |a Benedetto, Caroleo |e verfasserin |4 aut | |
| 700 | 1 | |a Luigi, Scalise |e verfasserin |4 aut | |
| 700 | 1 | |a Antonio, Cimellaro |e verfasserin |4 aut | |
| 700 | 1 | |a Lidia, Colangelo |e verfasserin |4 aut | |
| 700 | 1 | |a Giuseppe, Spaziano |e verfasserin |4 aut | |
| 700 | 1 | |a Gallelli, Luca |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current drug safety |d Sharjah : Bentham Science Publ., 2006 |g 14(2019), 3, Seite 233- |h Online-Ressource |w (DE-627)KFL000006491 |w (DE-600)2235202-8 |w (DE-576)306833492 |x 2212-3911 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2019 |g number:3 |g pages:233- |
| 856 | 4 | 0 | |u http://pharmazie.proxy.fid-lizenzen.de/fid/bentham-ejournals-pharmazie/www.eurekaselect.com/openurl/content.php?genre=article&issn=1574-8863&volume=14&issue=3&spage=233 |m X:KFL |x Verlag |y FID Access |z lizenzpflichtig |
| 912 | |a ZDB-1-BEJ | ||
| 912 | |a GBV_KFL | ||
| 912 | |a FID-PHARM | ||
| 912 | |a SSG-OLC-PHA | ||
| 935 | |i IMPORT_0628_prod_DARH_02 | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2019 |e 3 |h 233- | ||